Articles tagged with Alzheimer Disease
A team of researchers has identified two new genes that may play a role in the development of late-onset Alzheimer's disease. The study, published in the Journal of the American Medical Association, used genome-wide association analysis to identify the genes on chromosomes 2 and 19, which were found to be associated with AD.
An independent panel by the NIH determined that mental stimulation, exercise, and dietary supplements have insufficient evidence to delay or prevent Alzheimer's disease. The panel emphasized the need for research on objective measures of cognitive function and collaboration between clinicians and researchers.
Researchers at Mount Sinai School of Medicine found that Alzheimer's pathology begins with Amyloid-Beta oligomers in the brain, rather than previously thought amyloid plaques. The study suggests that these clumps, not plaques, are toxic to brain cells and may be a major target for new treatments.
Researchers found that volunteers high in neuroticism traits had lower volumes of gray matter in the frontal and medial temporal brain regions compared to those high in conscientious traits. This association suggests that personality may influence the rate of brain aging.
Researchers discovered that regions of the brain with increased amyloid-beta deposits are not the same as those with atrophy due to neuron loss. The study found that these regions can disrupt connections with the hippocampus, leading to neuron death.
Researchers have identified a gene, MTHFD1L, that increases the risk of developing late-onset Alzheimer's disease. The study found individuals with a specific variation in this gene are nearly twice as likely to develop Alzheimer's as those without it.
Researchers found that exclusive licensing deals are a tool for collaboration and risk management in product development, allowing innovators to manage risks while leveraging cooperation. The study analyzed over 200 exclusive licensing deals and suggests that granting rights to a sole partner can curb risk and incentivize cooperation.
IGIV has preserved thinking abilities and significantly reduced brain atrophy and ventricular enlargement in mild- to moderate-stage Alzheimer's patients. The study also found a dose-related effect on brain ventricular enlargement, suggesting IGIV may spare brain tissue.
A study found that individuals with Alzheimer's disease experience lean mass loss, which is associated with decreased brain volume and cognitive performance. This loss of muscle mass may be an early indicator of the progression of dementia, highlighting its potential as a sensitive measure for changes in body composition.
A new study by University of Iowa researchers found that individuals with amnesia retain emotional responses to happy and sad movie clips, even when they cannot recall the content. This challenges traditional views on memory loss and highlights the importance of caring for patients with Alzheimer's disease.
The American Academy of Neurology has issued a guideline to help determine when people with Alzheimer's disease or another type of dementia should stop driving. The guideline recommends doctors use the Clinical Dementia Rating (CDR) scale to identify individuals at increased risk of unsafe driving. Caregivers and family members can als...
Researchers have discovered that targeting the blood-brain barrier can slow the accumulation of a protein associated with Alzheimer's disease. The study shows that activating a certain receptor in the brain can increase the expression of a blood-brain barrier protein that transports beta-amyloid out of the brain.
Researchers found a dietary pattern involving high intakes of salad dressing, nuts, fish, tomatoes, poultry, fruits, and cruciferous and dark leafy vegetables to be significantly associated with reduced Alzheimer's disease risk. This pattern reflects multiple pathways in the development of Alzheimer's disease, including the impact of v...
Scientists are developing new medications to block abnormal clumps of amyloid-beta protein in the brain, which may slow Alzheimer's disease progression. Clinical trials could lead to new treatments within 5-10 years if successful.
Researchers are exploring the role of beta defensins in chronic inflammation within the aging human brain, including Alzheimer's disease. Preliminary findings suggest that beta defensins may contribute to neuronal cell death due to compromised immunomodulation.
Scientists have developed a low-cost behavioral assessment that can detect changes in the progression of mild cognitive impairment (MCI) and predict Alzheimer's disease. The test measures information processing capacity, which correlates with hippocampal degradation and decline in brain function.
Researchers found that rapamycin improved learning and memory in Alzheimer's-susceptible mice, correlating with lower brain damage. The study used two different mouse models of early Alzheimer's, both showing similar results.
Researchers found truncated peptides form active ion channels causing cell death and memory loss, contradicting previous effective treatments. A new approach aims to control these ion channels for an effective treatment.
Researchers developed a self-administered test to screen for early dementia, detecting 80% of mild cognitive impairments. The Self-Administered Gerocognitive Examination (SAGE) can help identify individuals with Alzheimer's disease at an early stage, improving treatment outcomes.
McGill University researcher Prof. Claudio Cuello has genetically manipulated rats to emulate Alzheimer's disease in humans, allowing for the study of a suspected 'latent phase' previously impossible to predict. This breakthrough enables researchers to develop new treatments for the devastating brain condition.
Researchers at Cold Spring Harbor Laboratory found that blocking PI3 kinase signaling improves memory in aging fruit flies, reducing β-amyloid deposits. The study sheds light on the role of PI3 kinase in Alzheimer's disease and suggests potential therapeutic targets.
A new enzyme-linked immunosorbent assay can detect Alzheimer's disease by measuring high molecular weight A-Beta oligomers in spinal fluid. The test showed direct correlation between A-Beta oligomer levels and memory impairment, enabling early diagnosis of the disease.
Researchers have discovered elderly people with super-sharp memory who escaped formation of brain tangles, a hallmark of Alzheimer's disease. These 'super-aged' individuals were found to be protected from the negative effects of tangle formation.
Research suggests that microglia, immune cells in the brain, play a significant role in neuron loss during Alzheimer's disease. Stressed nerve cells secrete chemical messengers that attract microglia, leading to inflammation and elimination of neurons.
A study of 1,158 participants with mild cognitive impairment showed rapid memory and thinking skill declines compared to those without cognitive problems. The decline in skills was twice as fast for those with mild cognitive impairment than those without, while four times faster for those with Alzheimer's disease.
A new study by Rush University Medical Center researchers found that people with Alzheimer's disease experience a rate of cognitive decline four times greater than those with no cognitive impairment. The study, published in Neurology, also revealed no significant racial differences in the progression of the disease.
Researchers found amyloid plaques in healthy elderly individuals with disrupted brain connections, similar to those with Alzheimer's disease. This suggests that Alzheimer's may begin quietly, eroding brain networks before symptoms appear.
Researchers have discovered a molecule, Affibody, that can prevent the formation of toxic protein clumps in the brain and promote their clearance. This breakthrough could lead to new possibilities in Alzheimer's therapy development, offering hope for preventing the disease.
A team of scientists discovered a molecule that can prevent a toxic protein involved in Alzheimer's disease from building up in the brain. Using fruit flies engineered to develop a fly equivalent of Alzheimer's disease, they showed that the same molecule effectively cures the insects of the disease.
Researchers at Mayo Clinic have found a novel theory about how the insulin-degrading enzyme (IDE) gene influences the risk of Alzheimer's disease. The study suggests that too little IDE expression may promote disease development, while increased expression appears to protect against it.
Researchers found a greater number of protein clumps linked to Alzheimer's, especially among children of mothers with the disease. The study suggests a genetic mechanism is involved and may help explain why family history is a significant risk factor for the brain disease.
Researchers at the University of Tennessee have developed a new Alzheimer's test called CST, which is more than 95 percent effective in detecting cognitive abnormalities. The test is designed to be simple and accessible for medical professionals and patients, providing an objective way to determine the presence of Alzheimer's disease.
Research suggests that amyloid-beta protein, a primary component of Alzheimer's plaques, is an antimicrobial peptide part of the innate immune system. A-beta inhibits the growth of certain pathogens and its accumulation may be triggered by chronic activation of the innate immune system.
Scientists have developed a new model using sea squirts to test anti-Alzheimer's drugs, which could lead to breakthroughs in disease treatment. The study found that dosing sea squirt tadpoles with a mutant protein resulted in aggressive plaque development and behavioral defects, which were reversed by an experimental drug.
A study published in Archives of General Psychiatry found that individuals with a sense of purpose in life have a reduced risk of developing Alzheimer's disease and mild cognitive impairment. Those with higher levels of purpose were approximately 2.4 times less likely to develop the disease.
A study found that nearly four in 10 TIA and minor stroke patients exhibit deficits in executive functions, including speed of mental processing and abstraction. Researchers emphasize the importance of using specific measures to detect cognitive impairment in these patients.
Researchers found that rapamycin rescued learning and memory deficits in a mouse model of Alzheimer's disease. The study also showed reduced brain lesions similar to those seen in human Alzheimer's patients.
The study found that dementia incidence rates increase exponentially with age in both men and women past age 90. Researchers estimate that the number of Americans aged 90 and older will reach 8.7 million by 2050, making dementia a significant public health concern.
Researchers at NYU School of Medicine have found that elevated levels of phosphorylated tau231 may predict future memory decline and loss of brain gray matter in healthy adults. High levels of P-tau231 are associated with reductions in medial temporal lobe gray matter, suggesting its potential as a diagnostic tool for Alzheimer's disease.
A University of Michigan study found that untreated visual disorders in the elderly are significantly more likely to develop Alzheimer's disease. Early treatment of these problems may delay the onset of dementia, but many elderly individuals lack adequate vision coverage.
A computer simulation of protein malfunction related to Alzheimer's disease was created by researchers at Universitat Autonoma de Barcelona and University of Stockholm. The model shows that ApoE4 loses its functional structure in the presence of Amyloid beta, but not ApoE2 and ApoE3 forms.
Researchers found that amyloid beta peptides induce calcium waves in astrocyte networks, which could clarify what causes Alzheimer's disease and suggest new drug targets. The study provides a potential link between the accumulation of Amyloid beta fragments and sustained disruption of calcium balance within cells.
Researchers at UCLA have made a breakthrough in identifying the earliest signs of Alzheimer's disease using brain imaging techniques. By tracking subtle changes in brain structure over time, they were able to predict a brain's progression to Alzheimer's disease, allowing for potential early interventions.
Research found that patients with Alzheimer's were 4.6 times more likely to have mental lapses than those without the disease. Cognitive fluctuations include excessive daytime sleepiness, staring into space, and disorganized or illogical thinking.
A study found that people with three or four of the following symptoms are more likely to have Alzheimer's disease: feeling drowsy, disorganized thinking, staring into space, and lethargy. Those with mental lapses also had more severe symptoms and poorer cognitive performance than those without lapses.
Studies implicate beta amyloid protein in shared disease mechanisms with Alzheimer's, Down syndrome, and atherosclerosis. Damage to microtubule network disrupts cholesterol metabolism and insulin signaling.
A TGen-led team has identified three kinases that cause hyperphosphorylation of tau protein, leading to the dismantling of microtubule bridges within brain cells. This process disrupts synaptic connections and can lead to memory loss and thinking problems associated with Alzheimer's disease.
A new eye test technique enables real-time measurement of brain cell death, refining diagnosis and tracking disease progress in Alzheimer's. The method uses fluorescent markers to directly observe retinal nerve cell death, which could lead to successful reversal of the disease with treatment.
Researchers have identified a fast-acting compound, benzylquinolone carboxylic acid (BQCA), that improves cognitive function impairments in mice with progressive Alzheimer's disease. BQCA works by boosting weak signals of the M1 muscarinic acetylcholine receptor and inhibiting production of amyloid beta, a marker of the disease.
A study published in the Journal of Neuroscience found a link between loss of smell function and amyloid protein accumulation in the brain, potentially serving as an early diagnostic tool for Alzheimer's disease. Researchers suggest that olfactory dysfunction may be used to detect the disease prior to substantial brain degeneration.
Researchers found a 'longevity gene' associated with slower cognitive decline and reduced risk of dementia and Alzheimer's disease. The CETP gene variant alters protein function, leading to higher HDL cholesterol levels and increased protection against age-related illnesses.
A new study found that healthy older adults with subjective cognitive impairment (SCI) are 4.5 times more likely to progress to mild cognitive impairment (MCI) or dementia than those without SCI. Over a seven-year period, 54% of SCI individuals showed further cognitive decline, compared to 15% of non-SCI individuals.
A combination of nutrients, including uridine, choline, and DHA, has shown promise in improving verbal memory in patients with mild Alzheimer's disease. The study found that 40% of treated patients improved performance in a test of verbal memory, while 24% of control subjects showed improvement.
Researchers are conducting a Phase 2 clinical trial to evaluate the safety and effectiveness of CERE-110, a viral-based gene transfer system delivering nerve growth factor to slow Alzheimer's disease progression. The study aims to delay AD symptoms and progression in patients with mild to moderate Alzheimer's.
University of Central Florida researchers have revealed a previously unknown mechanism that may drive the early brain function deterioration of Alzheimer's victims, potentially leading to preventive treatment. The discovery uses an existing cell research technique to accelerate the search for treatments.
A new brain scan, diffusion tensor imaging (DTI), has been shown to detect changes in the hippocampus that are associated with memory decline. DTI-MRI scans were found to be more accurate than traditional MRI in identifying changes related to Alzheimer's disease.
A new study published in the Journal of Alzheimer's Disease suggests that long-term cell phone exposure may protect against and even reverse Alzheimer's disease. The research found that electromagnetic waves generated by cell phones erased brain deposits of beta-amyloid, a hallmark of Alzheimer's disease, in mice.
A new study identifies βCTF, a small protein found in APP, as a novel factor contributing to Alzheimer's disease-related endosome abnormalities. Elevated levels of βCTF cause specific pattern of endosome defects similar to brain cells in Alzheimer's disease.
A study by Dr. Gregory A. Elder found that presenilin-1 plays a role in the vascular pathology associated with Alzheimer disease, while another study discovered that osteopontin contributes to allergic contact dermatitis. Weakened Plasmodium parasites also elicit a protective immune response.
A recent study found that people with Alzheimer's disease were less likely to develop cancer, while those with cancer were less likely to develop Alzheimer's. The study suggested that these two conditions may be linked, offering potential avenues for new treatments and a better understanding of both diseases.